share_log

Takeda Pharmaceutical | 6-K: Takeda intends to rapidly initiate the first global Phase 3 trials of TAK-861, an oral orexin agonist, in narcolepsy type 1 in first half of fiscal year 2024

SEC ·  Feb 9 19:09
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.